Leflunomide counter s cardiac hypertrophy

Area of Science:

• Cardiology
• Pharmacology
• Molecular Biology

Background:

• Cardiac hypertrophy (CH) is a significant risk factor for heart failure and mortality.
• Current therapeutic strategies for CH lack load-independent mechanisms.
• Targeting hypertrophy signaling pathways remains a critical unmet need in cardiovascular medicine.

Purpose of the Study:

• To investigate the therapeutic potential of the anti-inflammatory drug leflunomide in cardiac hypertrophy.
• To elucidate the underlying molecular mechanisms of leflunomide's action on CH.
• To explore leflunomide as a repurposed drug for treating CH.

Main Methods:

• Utilized mouse models of cardiac hypertrophy induced by aortic banding and angiotensin-II infusion.
• Employed cultured cells stimulated with hypertrophy-inducing agonists.
• Investigated the impact of leflunomide on CH, cardiac dysfunction, and fibrosis.
• Analyzed the effects of leflunomide on Akt (protein kinase B, PKB) signaling pathways.

Main Results:

• Leflunomide significantly antagonized cardiac hypertrophy, dysfunction, and fibrosis in preclinical models.
• The anti-hypertrophic effects of leflunomide were independent of its anti-inflammatory properties.
• Leflunomide was found to inhibit Akt (protein kinase B, PKB) signaling, mediating its beneficial effects.
• The study discusses mechanisms of Akt activation and leflunomide's interaction with this pathway.

Conclusions:

• Leflunomide demonstrates significant therapeutic potential for cardiac hypertrophy through a novel mechanism involving Akt signaling inhibition.
• Repurposing leflunomide offers a promising, readily available therapeutic option for CH.
• Further research into leflunomide's mechanisms and clinical efficacy in CH is warranted.